CEL SCI
NYSE: CVMVienna, US · Colorado corporation
CEL-SCI is a biotechnology company developing cancer immunotherapy products, including its lead candidate Multikine for head and neck cancer, which showed a survival benefit in a Phase III trial. It also develops the early-stage LEAPS platform for rheumatoid arthritis and other autoimmune and infectious diseases.
BiotechHealthtech
Founders & leadership
PB
Patricia B. PrichepExecutive
ET
Eyal TalorExecutive
GR
Geert R. KerstenExecutive
DH
Daniel H. ZimmermanExecutive
JC
John CiprianoExecutive
Board
PY
Peter YoungBoard director
BB
Bruno BaillavoineBoard director
AG
Alexander G. EsterhazyBoard director
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 2 of 3 rounds · 2017–2018
▶$78KraisedJul 2018 · 4 investors · BiotechnologyRule 506(b)
▶$78KraisedJul 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter R. YoungDirector
- Robert WatsonDirector
- Geert KerstenExecutive Officer, Director
- Eyal TalorExecutive Officer
- John CiprianoExecutive Officer
- Bruno BailavoineDirector
- Patricia B. PrichepExecutive Officer
- Daniel H. ZimmermanExecutive Officer
- Offering amount
- $78K
- Amount sold
- $78K
- Minimum investment
- $10K
- Sales commissions
- $5.5K
- Placement agents
- H.C. Wainwright
- First sale
- Jul 2018
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$1.5MofferedJul 2017 · 6 investors · PharmaceuticalsRule 506(b)
▶$1.5MofferedJul 2017 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Patricia PrichepExecutive Officer
- Daniel ZimmermanExecutive Officer
- Alexander EsterhazyDirector
- Geert R. KerstenExecutive Officer
- Bruno BailavoineDirector
- John CiprianoExecutive Officer
- Peter YoungDirector
- Eyal TalorExecutive Officer
- Offering amount
- $1.5M
- Minimum investment
- $50K
- First sale
- Jun 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
▶$1MraisedFeb 2017 · 2 investors · PharmaceuticalsRule 506(b)
▶$1MraisedFeb 2017 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter R. YoungDirector
- Patricia B. PrichepExecutive Officer
- Eyal TalorExecutive Officer
- Geert R. KerstenExecutive Officer, Director
- Bruno BaillavoineDirector
- Daniel H. ZimmermanExecutive Officer
- Alexander G. EsterhazyDirector
- John CiprianoExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1K
- Sales commissions
- $70K
- Proceeds to insiders
- $142K
- First sale
- Feb 2017
- Incorporated
- Corporation, Colorado
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with CEL SCI for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $162.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $134.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $104.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2000 | $379.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | — |
| Department of Health and Human Services | Phase I | 1998 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does CEL SCI do?
- CEL-SCI is a biotechnology company developing cancer immunotherapy products, including its lead candidate Multikine for head and neck cancer, which showed a survival benefit in a Phase III trial. It also develops the early-stage LEAPS platform for rheumatoid arthritis and other autoimmune and infectious diseases.
- How much funding has CEL SCI raised?
- CEL SCI has disclosed $1.1M raised across 2 of its 3 known rounds.
- Where is CEL SCI headquartered?
- CEL SCI is headquartered in Vienna, US.